Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Formative Research

Date Submitted: Jan 25, 2023
Date Accepted: Mar 27, 2023

The final, peer-reviewed published version of this preprint can be found here:

Patient and Provider Perspectives on Symptom Monitoring During Outpatient Chemotherapy: Interview Study

Chen L, Bartel C, Cai X, Cheng Y, Perer A, McClaine S, Kairis E, Durica KC, Huang W, Low CA

Patient and Provider Perspectives on Symptom Monitoring During Outpatient Chemotherapy: Interview Study

JMIR Form Res 2023;7:e46001

DOI: 10.2196/46001

PMID: 37067857

PMCID: 10131985

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Patient and Provider Perspectives on Symptom Monitoring during Outpatient Chemotherapy: Interview Study

  • Leeann Chen; 
  • Christianna Bartel; 
  • Xinlu Cai; 
  • Yang Cheng; 
  • Adam Perer; 
  • Sean McClaine; 
  • Elizabeth Kairis; 
  • Krina C. Durica; 
  • Weiyu Huang; 
  • Carissa A. Low

ABSTRACT

Background:

Fluctuating symptoms and side effects are common during outpatient cancer treatment, and approaches to monitoring symptoms vary widely across providers, patients, and clinical settings. To design a remote symptom monitoring system that patients and providers find to be useful, it may be helpful to understand current clinical approaches to monitoring and managing chemotherapy-related symptoms among patients and providers and assess how more frequent and systematic assessment and sharing of data could improve patient and provider experiences.

Objective:

The goals of this study were to learn about patient and provider perspectives on monitoring symptoms during chemotherapy, to understand barriers and challenges to effective symptom monitoring at one institution, and to explore the potential value of remote symptom monitoring between provider visits.

Methods:

A total of 15 patients and 7 oncology providers participated in semi-structured interviews. Interviews were transcribed and coded using an iterative thematic analysis approach.

Results:

Four main themes were discussed by patients and providers: (1)Asynchronous nature of current methods to tracking and managing symptoms, (2) variability in reported symptoms due to patient factors, (3) limitations of existing communication channels, and (4) potential value of real-time remote symptom monitoring during chemotherapy.

Conclusions:

Both patients and providers highlighted significant challenges of asynchronous, patient-initiated, phone-dependent symptom monitoring and management. Oncology patients and providers reported that more routine remote monitoring of symptoms between visits could improve patient- provider communication, prepare patients for subsequent chemotherapy cycles, and facilitate provider insight and clinical decision-making with regard to symptom management.


 Citation

Please cite as:

Chen L, Bartel C, Cai X, Cheng Y, Perer A, McClaine S, Kairis E, Durica KC, Huang W, Low CA

Patient and Provider Perspectives on Symptom Monitoring During Outpatient Chemotherapy: Interview Study

JMIR Form Res 2023;7:e46001

DOI: 10.2196/46001

PMID: 37067857

PMCID: 10131985

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.